Connect with us

Technology

Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis

Published

on

News Summary:

Waters new LC-MS grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of mRNA vaccines, personalized cancer therapies, and innovative drugs for genetic disorders.Novel digestion enzymes deliver complete RNA sequence coveragei for more confident characterization, while new LC-MS-grade reagents increase sensitivity and improve detection accuracy of RNA components.iiNew waters_connect™ MAP Sequence software accelerates RNA oligonucleotide mapping using semi-automated workflows that reduce data processing time over manual techniques, enabling routine monitoring of key product attributes.

MILFORD, Mass., Oct. 14, 2024 /PRNewswire/ — Waters Corporation (NYSE: WAT) today introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LC-MS) analysis. When used together in a workflow, these bioseparations tools help accelerate and improve the development of innovative large molecule RNA-based pharmaceuticals, such as CRISPR sgRNA and mRNA therapeutics.

Large molecule RNA (ribonucleic acid) therapeutics represent some of the most exciting and potentially life-saving developments in pharmaceuticals today. They include new and more effective vaccines for diseases like COVID-19, personalized cancer treatments, as well as emerging CRISPR RNA therapies that address challenging genetic conditions, such as sickle cell anemia.

“As RNA-based therapies are prepared for widespread use, more direct composition measurements are needed to ensure stability, safety, and effectiveness for patients,” said Erin Chambers, Vice President, Consumables and Lab Automation at Waters Corporation. “The combination of Waters enzymes, reagents, and software are specially designed to simplify the confirmation of sequence and modifications of complex molecules. These analytical tools can accelerate RNA therapeutic development and lower barriers for use by LC-MS non-experts.”

“As innovators looking to help our customers advance nucleic acid-based therapies and reduce the burden of serious diseases, we are always seeking new technologies to improve characterization and accelerate development,” said Arnaud Delobel, PhD, R&D and Innovation Director at Quality Assistance S.A. and beta tester of the Waters RNA analytical tools. “Waters new enzymes efficiently digest mRNA and sgRNA with short incubation times and data processing in MAP Sequence allows the user to obtain reproducible results quickly with confidence.”

The Waters RNA analytical tools include:

Enzymes: Two novel enzymes, RapiZyme™ MC1 and RapiZyme Cusativin, are used in a simplified three-step protocol that provides complete LC-MS sequence coverage over traditional digestion methods enabling more confident characterization of RNA molecules.iiiReagents: IonHance™ HFIP, an LC-MS-grade reagent, is formulated to improve ionization and delivers increased spectral clarity and detection accuracy of RNA components.Software: New MAP Sequence application on the waters_connect software platform simplifies RNA LC-MS oligo mapping workflows to accelerate analysis and data processing time over manual techniques using spreadsheets.

Used together within a workflow, the tools generate an LC-MS fingerprint to confirm product identity, purity, and efficacy. The tools improve sequence coverage, LC-MS spectral data quality, and data interpretation. Supported by the compliance-ready waters_connect software platform, these tools help transition LC and LC-MS-based digestion analysis from discovery and development to release and at-line process analytical testing.

Waters RapiZyme RNAses and IonHance HFIP are now available. The new MAP Sequence App on waters_connect software will be available on October 18, 2024.

Additional Resources

Learn more about the Waters RNA Analytical ToolsListen to our webinar “Cracking the Code: Analyzing mRNA and sgRNA with Advanced Enzymes, Mass Spectrometry, and Informatics on Oct. 16 at 11:00am ETJoin Waters at the PharmSci 360 conference for an expert session on “Oligo Mapping of Large RNA Therapeutics by Novel Enzyme Specificities” with Dr. Bala Addepalli, Waters Director, R&D New Modalities Portfolio on Oct. 21, at 11:00am ETFollow and connect with Waters via LinkedIn, Twitter, and Facebook

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

Waters, Rapizyme, IonHance, and waters_connect are trademarks of Waters Technologies Corporation.

Contact:
Janice Foley
Senior Public Relations Manager, Corporate Communications
Waters Corporation
janice_foley@waters.com
+1.617.823.5555

i 100% RNA sequence coverage achieved for HPRT sgRNA digested with RapiZyme MC1 and RapiZyme Cusativin compared to traditional digestion methods such as RNase T1. Waters Application Note 720008539EN: “Tunable Digestions of RNA Using RapiZyme RNases to Confirm Sequence and Map Modifications” .

ii IonHance HFIP reagents are certified to contain less than 100 ppb sodium and less than 100 ppb potassium content, resulting in reduced adduct formation and improved sensitivity of RNA detection compared to commercially available HFIP. Waters Application Note 720008540EN: “Evaluating IonHance Hexafluoroisopropanol (HFIP) for Enhanced LC-MS Oligonucleotide Analysis”

iii Waters RapiZyme RNase protocol simplifies sample preparation with three steps including reagent preparation, RNA digestion, and heat inactivation without the need to add chemical denaturants and enzyme inhibitors.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Department of Health – Abu Dhabi and Fred Hutchinson Cancer Center collaborate on cancer research and personalized prevention

Published

on

By

ABU DHABI, UAE, May 13, 2026 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), regulator of the healthcare sector in the emirate, together with the Abu Dhabi Public Health Center (ADPHC), today announced the execution of a Memorandum of Understanding (“MOU”) with Fred Hutchinson Cancer Center (Fred Hutch), one of the world’s leading cancer research institutions and home to three Nobel laureates.

By pairing Abu Dhabi’s unified clinical and genomic data infrastructure, sovereign AI capabilities and governed data environments with Fred Hutch’s globally renowned research engine, the ensuing collaborations will pave the way to shortening the distance between scientific discovery and patient benefit, for Abu Dhabi’s community and beyond.

Among the projected collaborations, the two organizations will consider leveraging Abu Dhabi’s intelligent health system, and layering Fred Hutch’s world-class science onto the secure, high-quality, real-world data foundation Abu Dhabi has built. That foundation includes the emirate’s pioneering liquid biopsy programme launched last year, one of the first national-scale efforts of its kind anywhere in the world. Alongside Abu Dhabi’s AI multi-cancer early detection work, and the world’s largest clinically integrated population-scale genomics programme – with nearly one million genomes sequence.

During his visit to the center, HE Mansoor Ibrahim Al Mansoori, Chairman of DoH commented: “Cancer is one of the defining health challenges of our time, and progress depends on combining world-class science with population-scale data, advanced AI, and research. In Abu Dhabi, we have built an AI-enabled health system that ‘cares before it cures, delivering prevention at population scale. We are already achieving some of the highest early cancer detection rates in the world, and through our partnership with Fred Hutchinson Cancer Center we are committed to bringing breakthroughs to people in Abu Dhabi and beyond.”

“This MOU between Fred Hutch Cancer Center and the Abu Dhabi Department of Health underscores the power of working together to prevent and treat cancer,” said Thomas Lynch Jr., MD, president and director of Fred Hutch and holder of the Raisbeck Endowed Chair. “Our organizations share a deep commitment to research and to provide the highest levels of cancer prevention, diagnosis and care to our communities, and we are excited to bring our expertise, tools and datasets together to identify unique approaches to cancer care and research in pursuit of our boldest goals.”

Photo – https://mma.prnewswire.com/media/2979204/DoH_Abu_Dhabi.jpg
Logo- https://mma.prnewswire.com/media/2714371/5968536/DoH_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/department-of-health—abu-dhabi-and-fred-hutchinson-cancer-center-collaborate-on-cancer-research-and-personalized-prevention-302770894.html

SOURCE The Department of Health – Abu Dhabi

Continue Reading

Technology

L’Mychele & Associates Founder LaKessia Hill Completes North Texas FWC Hospitality Program (FIFA World Cup) and Appears on The Jeff Crilley Show

Published

on

By

DALLAS, May 13, 2026 /PRNewswire/ — L’Mychele & Associates LLC is proud to announce two significant milestones for the growing strategic meetings and events firm: Founder & CEO LaKessia Hill has successfully completed the North Texas FWC Organizing Committee’s Hospitality Program and was recently featured on The Jeff Crilley Show.

These accomplishments reflect the company’s continued momentum within the hospitality, tourism, and events industries as L’Mychele & Associates expands its presence through strategic partnerships, leadership engagement, and elevated client experiences.

The completion of the North Texas FWC Hospitality Program further strengthens the company’s commitment to delivering intentional, guest-centered experiences rooted in strategy, hospitality, and meaningful connection — values that are central to the L’Mychele & Associates brand.

In addition, Hill recently joined veteran journalist and media personality Jeff Crilley on The Jeff Crilley Show to discuss her entrepreneurial journey, the vision behind L’Mychele & Associates, and the company’s approach to creating experiences as bold as its clients’ goals.

“Both opportunities represent growth, visibility, and the continued evolution of our brand,” said Hill. “Hospitality is more than service — it’s about creating intentional moments that leave lasting impressions. Being recognized through the hospitality program and having the opportunity to share our story on The Jeff Crilley Show were both incredibly meaningful experiences.”

Known for its consultative and strategy-first approach, L’Mychele & Associates specializes in executive summits, conferences, nonprofit galas, incentive experiences, corporate meetings, and curated social gatherings. The firm partners with organizations, brands, and leaders to transform ideas into impactful experiences through strategic planning, management, and execution.

Guided by the company’s signature philosophy — “The Art of Listening. The Science of Execution.” — L’Mychele & Associates continues to position itself as a strategic partner within the meetings, events, and hospitality industries.

The episode of The Jeff Crilley Show featuring LaKessia Hill is now available across multiple platforms, including YouTube, Facebook, LinkedIn, and Transistor.

About L’Mychele & Associates LLC

L’Mychele & Associates LLC is a Dallas-based strategic meetings and events firm specializing in executive summits, corporate meetings, conferences, nonprofit events, incentive experiences, and curated social gatherings. The company is known for blending strategy, hospitality, and execution to create experiences that drive connection and lasting impact.

Media Contact

LaKessia Hill
Founder & CEO, L’Mychele & Associates LLC
469-402-7825

LaKessia@LMychele.com
www.LMychele.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/lmychele–associates-founder-lakessia-hill-completes-north-texas-fwc-hospitality-program-fifa-world-cup-and-appears-on-the-jeff-crilley-show-302770319.html

SOURCE L’Mychele & Associates LLC

Continue Reading

Technology

HBX GROUP ANNOUNCES HALF YEAR 2026 FINANCIAL RESULTS

Published

on

By

LONDON, May 13, 2026 /PRNewswire/ — HBX Group International plc (HBX Group, the Company, the Group, HBX.SM) announces its Half Year 2026 results for the six months ended 31 March 2026.  

TTV up +17% to €3.8bn, and Revenue of €309m, up +1% YoY at constant currency, reflecting targeted commercial and strategic actions to prioritise growth and capture market share, partly offset by disruption from the Middle East conflictAdjusted EBITDA up +9% at constant currency to €163m, with margin of 53% expanding +4ppts in constant currency. Profit after tax was €28m (H1 25: €(227)m).Strong cash generation with 103% cash conversion and leverage at 1.7x Adjusted Net Debt / Adjusted EBITDA. S €100m share buyback programme and a 7.5 cents per share (c.€18m) interim dividend.Executing the strategic building blocks, including the acquisition of Bridgify announced today.FY26E guidance revised to reflect the impact of Middle East conflict and macroeconomic uncertainty. New FY26 guidance is for constant currency TTV growth +11% to +15%, Revenue growth -4% to +1% and Adjusted EBITDA growth -5% to -2%, and Operating Free Cash Flow conversion between 90% and 100%. Medium-term guidance is unchanged.

First half 2026 Financial Performance Summary1

6 months
ended 31
March 2026

6 months
ended 31
March 2025

Change
constant
currency2

Change 

Total Transaction Value (TTV) (€m)

3,770

3,370

+17 %

+12 %

Revenue (€m)

309

319

+1 %

-3 %

Adjusted EBITDA (€m)

163

159

+9 %

+3 %

Delivering profitable growth

Group TTV increased to €3.8bn in the first half, up +17% at constant currency. TTV contribution increased from shorter lead-time bookings, Third Party Supply and Online Travel Agents.

Revenue of €309m, increased +1% in constant currency. Take rate was 8.2%, down 1.3ppts year‑on‑year.

Adjusted EBITDA increased 9%, with margin +4ppts.

Net finance costs were €35m, 77% lower than the prior year. The tax charge was €16m. Adjusted Earnings were €83m, up +44% at constant currency.

Delivering commercial milestones in line with strategy

Commercial progress in H1 2026 reflected HBX Group’s strategy to expand its global travel ecosystem and drive profitability through AI-driven operational efficiency and commercial performance. Key developments included new distribution partnerships in Asia-Pacific, acquisitions such as Bridgify and PerfectStay to strengthen experiences and dynamic capabilities, and new platform and fintech initiatives.

HBX group also continued embedding AI across products and operations, including AI-powered solutions for Bedsonline and HotelTech, while scaling internal AI agents already delivering measurable savings and supporting more than 120 identified use cases, reinforcing the Group’s connected B2B travel ecosystem strategy.

Regional performance and trading dynamics

TTV grew in double-digits in all three regions, up +18% in the Americas and +16% in both MEAPAC and Europe, at constant currency.

In Europe, TTV growth was supported by strong intra‑regional and domestic travel. Asia Pacific up +18%, partly offset by slower growth in the Middle East and disruption on some Europe-Asia corridors. In the Americas, TTV was predominantly driven by domestic demand.

Middle East impact and near‑term outlook

Since late February, the escalation of the conflict in the Middle East has impacted travel demand across affected destinations and selected international corridors, resulting in increased volatility, shorter booking windows and reduced near‑term visibility. The impact of this on H1 Group TTV growth was approximately 1ppt.

HBX Group implemented dynamic pricing, inventory reallocation and active partner support. Demand outside affected corridors has been more resilient.

Cost discipline, cash generation and capital allocation

Underlying operating costs fell by 5%. Performance was supported by productivity initiatives, automation and AI.

On a last 12-month basis, Operating Free Cash Flow was €447m, with cash conversion of 103% over the last 12 months. Adjusted Net Debt at 31 March 2026 stood at €741m.

Outlook

The Group started FY26 with strong performance. Since late February, trading conditions have been adversely impacted by the escalation of the conflict in the Middle East and broader geopolitical uncertainty.

The Group has revised its FY26 guidance. Updated outlook reflects a -4ppt effect of the Middle East conflict on TTV growth. Assumes four months of disruption with gradual stabilisation.

For the complete press release and disclaimer applicable to this information, please visit www.investors.hbxgroup.com

1 See financial statements for definitions of specific financial terms and KPIs, including any Alternative Performance Measures (APMs)
2 Constant currency changes exclude the impact of foreign exchange rate fluctuations by translating current year results at the exchange rates used in the prior year.

Contact: 
Clara Truyols
clatruyols@hbxgroup.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hbx-group-announces-half-year-2026-financial-results-302770897.html

SOURCE HBX Group

Continue Reading

Trending